Xbrane Biopharma Q1 2025: Initial take – Beat on revenue and EBIT - Redeye

Redeye's provides its initial take on Xbrane's Q1 report which confirmed a stronger than anticipated sequential volume growth for Ximluci of 36%. Revenue and EBIT beat our estimates—although primarily driven by one-offs in the quarter.

Länk till analysen i sin helhet: https://www.redeye.se/research/1102050/xbrane-biopharma-q1-2025-initial-take-beat-on-revenue-and-ebit?utm_source=finwire&utm_medium=RSS